Personalized treatments for adults with advanced cancer
Individualized Treatments in Adults With Relapsed/Refractory Cancers
This study is testing a personalized medicine approach for adults with advanced cancer to see if understanding their unique drug sensitivities can help doctors choose better treatment options.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 36 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Case Comprehensive Cancer Center Academic / other |
| Locations | 2 sites (Miami, Florida and 1 other locations) |
| Trial ID | NCT06024603 on ClinicalTrials.gov |
What this trial studies
This study focuses on a personalized medicine approach for adults with relapsed or refractory cancers, aiming to address therapy resistance and limited treatment options. Participants will undergo drug sensitivity testing and genomic screening to inform their physicians about specific drug sensitivities or resistances. Based on these results, physicians will guide treatment choices, potentially incorporating personalized drugs from an investigational platform. Treatment will not be administered as part of the trial, but participants may receive subsequent investigational treatments if standard options are exhausted.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with recurrent or refractory cancers who have exhausted standard treatment options.
Not a fit: Patients with newly diagnosed tumors or those without sufficient malignant tissue for testing may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide more effective, tailored treatment options for patients with advanced cancers who have limited choices.
How similar studies have performed: Other studies utilizing personalized medicine approaches have shown promise, suggesting potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants aged 18 years or older at the time of enrollment on this study of any gender, race, or ethnicity. * Patients with suspected or confirmed diagnosis of recurrent or refractory cancer with no curative treatment options. * Participants who have undergone at least two lines of previous therapy. * Participants who are scheduled for or have recently had biopsy or tumor excised (solid tumors) or bone marrow aspirate (blood cancers) or who have scheduled or recently had paracentesis or thoracentesis performed. * Participants willing to have a blood draw or buccal swab done for the purposes of genetic testing. * Participants willing to sign informed consent. Exclusion Criteria: * Participants who do not have malignant tissue available and accessible. * Participants for whom the amount of excised malignant tissue is not sufficient for the ex vivo drug testing and/or genetic profiling. * Participants with newly diagnosed tumors and tumors that have high (\>90%) cure rate with safe standard therapy.
Where this trial is running
Miami, Florida and 1 other locations
- Florida International University — Miami, Florida, United States (Recruiting)
- Lerner College of Medicine, Cleveland Clinic Florida — Weston, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Jorge Manrique-Succar, MD — Lerner College of Medicine, Cleveland Clinic Florida
- Study coordinator: Jorge Manrique-Succar, MD
- Email: manriqj@ccf.org
- Phone: (954) 659-5000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.